MindBio Reports Sustained Antidepressant Response Post Microdosing Treatment

MindBio Therapeutics Corp. has announced that three months post cessation of an 8-week microdosing treatment, there is a 62.8% reduction in depressive symptoms. The Phase 2A clinical trials showcased a significant and sustained antidepressant response in patients using MB22001, a proprietary take-home microdose of LSD.

The trials demonstrated excellent safety, adherence, and tolerance, consistent with Phase 1 results. A manuscript has been submitted to the British Journal of Psychiatry for peer review. MindBio is the only organization running multiple Phase 2B clinical trials approved for take-home use of psychedelic medicine.

MindBio's approach contrasts with traditional clinical trials that use large hallucinogenic doses administered in clinics. The company believes microdosing is a scalable, effective, and affordable way to treat patients. Ongoing Phase 2B trials target depression and cancer, with another approved for PMS and PMDD.